Experimental combo for lung cancer shows promise but study cut short
NCT ID NCT04984811
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested a combination of two drugs—NT-I7 and atezolizumab—in people with advanced non-small cell lung cancer that had not been treated before. The goal was to see if the combo could shrink tumors. However, the study was stopped early and only enrolled 33 out of a planned 83 participants, so the results are not conclusive.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- efineptakin alfa (NT-I7) plus atezolizumab (Tecentriq)
- What this could lead to
- If it works, this combination could improve tumor shrinkage rates in advanced lung cancer patients who have not had prior treatment.
- What could go wrong
- The trial was terminated early with only 33 participants, so results are limited. It is a small, single-arm study with no comparison group, making it hard to know if the combination is truly better than standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
BRCR Medical Center
Plantation, Florida, 33322, United States
-
East Carolina University
Greenville, North Carolina, 27834, United States
-
Eastern CT Hematology & Oncology Associates
Norwich, Connecticut, 06360, United States
-
Florida Cancer Specialists - East Research Office
West Palm Beach, Florida, 33401, United States
-
Florida Cancer Specialists - North Research Office
St. Petersburg, Florida, 33705, United States
-
Florida Cancer Specialists - South Research Office
Fort Myers, Florida, 33916, United States
-
Goshen Center for Cancer Care
Goshen, Indiana, 46526, United States
-
MaineHealth Cancer Care
South Portland, Maine, 04106, United States
-
Norton Cancer Institute
Louisville, Kentucky, 40217, United States
-
OHSU Knight Cancer Institute
Portland, Oregon, 97239, United States
-
Pikeville Medical Center, Inc.
Pikeville, Kentucky, 41501, United States
-
Renovatio Clinical - El Paso
El Paso, Texas, 79915, United States
-
Renovatio Clinical - The Woodlands
The Woodlands, Texas, 77380, United States
-
Summit Health Medical Center
Florham Park, New Jersey, 07932, United States
-
TOI Clinical Research
Cerritos, California, 90703, United States
-
Tennessee Oncology - Chattanooga
Chattanooga, Tennessee, 37404, United States
-
Tennessee Oncology - Nashville
Nashville, Tennessee, 37203, United States
-
Thompson Cancer Survival Center
Knoxville, Tennessee, 37916, United States
-
TidalHealth Peninsula Regional, Inc.
Salisbury, Maryland, 21801, United States
-
University Cancer and Blood Center
Athens, Georgia, 30607, United States
-
University of South Alabama
Mobile, Alabama, 36604, United States
-
Zangmeister Cancer Center
Columbus, Ohio, 43219, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Can a targeted pill keep lung cancer from returning?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?
- Can a targeted pill outsmart a tough lung cancer mutation?